Journal of Clinical Virology publishes positive outcome from CMX001 treatment against Adenovirus infection

This drug is being developed as a broad spectrum antiviral and trials are in progress for double stranded DNA viral infections, including adenovirus, cytomegalovirus, herpes simplex and the Epstein Barr virus, the JC polyoma virus the BK polyoma virus  and pox virus infection.
Kegg pathways Herpes simplex infection
Enhanced by Zemanta

No comments: